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Protease-activated receptor-1 (PAR1) is a G-protein–coupled recep-
tor uniquely activated by proteolysis. Thrombin, a coagulant pro-
tease, induces inflammatory responses and endothelial barrier
permeability through the activation of PAR1. Activated protein C
(APC), an anti-coagulant protease, also activates PAR1. However,
unlike thrombin, APC elicits anti-inflammatory responses and pro-
tects against endothelial barrier dysfunction induced by thrombin.
We found that thrombin and APC signaling were lost in PAR1-
deficient endothelial cells, indicating that PAR1 is the major effec-
tor of protease signaling. To delineate the mechanism responsible
for protease-selective signaling by PAR1, we examined the effect of
APC and thrombin on the activation of RhoA and Rac1, small
GTPases that differentially regulate endothelial barrier permeabil-
ity. Thrombin caused robust RhoA signaling but not Rac1 activa-
tion, whereas APC stimulated a marked increase in Rac1 activation
but not RhoA signaling, consistent with the opposing functions of
these proteases on endothelial barrier integrity. Strikingly, APC
signaling and endothelial barrier protection effects were abolished
in cells lacking caveolin-1, whereas thrombin signaling remained
intact. These findings suggest that compartmentalization of PAR1
in caveolae is critical for APC selective signaling to Rac1 activation
and endothelial barrier protection. We further report that APC
induces PAR1 phosphorylation and desensitizes endothelial cells to
thrombin signaling but promotes limited receptor cleavage and
negligible internalization and degradation even after prolonged
APC exposure. Thus, APC selective signaling and endothelial barrier
protective effects are mediated through compartmentalization of
PAR1 in caveolae and a novel mechanism of PAR1 signal regulation.
APC  endothelial  GPCR  Rac1  thrombin
The coagulant protease thrombin is generated in response tovascular injury and in thrombotic disease and drives fibrin
deposition and platelet activation, which are critical for hemo-
stasis and thrombosis (1). Thrombin also promotes pro-
inflammatory responses and disrupts endothelial barrier per-
meability (2). Protease-activated receptor–1 (PAR1), a
G-protein–coupled receptor (GPCR), is the predominant me-
diator of thrombin responses in cells. Thrombin activates PAR1
by cleaving the N-terminal domain, generating a new N terminus
that binds intramolecularly to the receptor to trigger transmem-
brane signaling (3). Synthetic peptides that represent the newly
formed N terminus of PAR1 can activate the receptor indepen-
dent of thrombin and proteolytic cleavage. Interestingly, throm-
bin and peptide agonists differ in their capacity to promote
endothelial barrier permeability and Ca2 mobilization (4).
These studies suggest that distinct cellular responses can be
evoked by the same receptor when activated proteolytically by
the tethered ligand versus untethered ‘‘free’’ synthetic peptide
agonists. Similar phenomena have been reported for other
GPCRs activated by different ligands and is a poorly understood
process termed functional selectivity or biased agonism (5).
Activated protein C (APC), an anti-coagulant protease, dis-
plays cytoprotective and anti-inflammatory activities and has
been shown clinically to reduce mortality of patients with severe
sepsis (6). APC is generated on the endothelial cell surface via
activation of protein C (PC) by the thrombin-thrombomodulin
complex (7). APC bound to endothelial protein C receptor
(EPCR) cleaves and inactivates factors Va and VIIa diminishing
thrombin generation and induces cellular responses through the
activation of PAR1 (8, 9). In contrast to thrombin, however, APC
elicits anti-inflammatory responses and promotes endothelial
barrier stabilization (10, 11). The mechanism by which APC
exerts anti-inflammatory and cytoprotective signaling in endo-
thelial cells is not fully understood.
Previous studies suggest that most endogenous PC is bound to
EPCR on the endothelial cell surface and cleaved by the
thrombin–thrombomodulin complex (12). The newly formed
APC is then poised to signal via direct activation of PAR1. Thus,
APC generation on the endothelial cell surface is linked mech-
anistically to PAR1 protective signaling. The cytoprotective and
anti-inflammatory responses induced by APC also require the
co-factor function of EPCR (9, 13). Interestingly, thrombomodu-
lin, EPCR and PAR1 partition into lipid rafts and co-fractionate
with caveolin-1, a structural protein essential for caveolae for-
mation in endothelial cells (14), suggesting that these proteins
reside at least partially in caveolar microdomains, a subtype of
lipid rafts (15, 16). However, whether caveolae are required for
APC activation of PAR1 signaling and endothelial barrier pro-
tective effects is not known.
Our studies here reveal a critical role for caveolae in APC, but
not thrombin, activation of PAR1 signaling and endothelial
barrier protection. These findings demonstrate an essential role
for caveolae in agonist selective signaling by PAR1. We further
show that APC promotes protective effects in endothelial cells
by desensitizing cells to thrombin signaling. Remarkably, how-
ever, APC causes limited PAR1 cleavage and negligible inter-
nalization and degradation, suggesting a novel mechanism for
regulation of PAR1 signaling.
Results
To determine whether PAR1 is essential for protease-selective
signaling, we examined thrombin and APC signaling in human
endothelial cells stably expressing a PAR1-specific shRNA (17).
Endothelial cells expressing PAR1 shRNA displayed minimal
PAR1 expression and signaling, whereas PAR2 signaling re-
mained intact [supporting information (SI) Fig. S1], indicating
loss of functional PAR1. In control cells, thrombin and APC
induced a similar biphasic increase in extracellular signal–
regulated kinase 1/2 (ERK1/2) activity (Fig. S2 A). However,
cells lacking PAR1 displayed minimal ERK1/2 activation in
response to various concentrations of thrombin or APC com-
pared with control cells (Fig. 1, S3, and S4). Thrombin-
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stimulated p38 MAP kinase activation was also lost in cells
deficient in PAR1 expression (Fig. S2C). In contrast to thrombin,
APC failed to stimulate p38 MAP kinase signaling in either
control or PAR1-deficient cells (Fig. S2B). These findings sug-
gest that PAR1, and not another receptor or factor, is critical for
thrombin and APC signaling in endothelial cells.
We next examined endothelial barrier permeability. Throm-
bin-stimulated endothelial barrier permeability was blocked in
cells preincubated with APC (Fig. 2A). These findings are
consistent with a role for APC in stabilization of endothelial
cell–cell junctions and protection against endothelial barrier
dysfunction induced by thrombin (10). We also evaluated the
effect of thrombin and APC on the activation of endogenous
RhoA and Rac1. Activation of RhoA promotes endothelial
barrier dysfunction, whereas Rac1 signaling has been implicated
in endothelial barrier stabilization (2). Thrombin induced RhoA
activation but not Rac1 signaling (Figs. 2B and 2C). In contrast,
APC stimulated Rac1 activation and minimal RhoA signaling
(Figs. 2B and 2C). Thus, thrombin and APC have the capacity
to elicit distinct signaling pathways and to differentially regulate
endothelial barrier permeability. Moreover, APC-stimulated
increase in Rac1 activation was lost in endothelial cells deficient
in PAR1 expression (Fig. 2D). These studies demonstrate that
endogenous PAR1 is essential for APC signaling and raise the
question of how activation of the same receptor by two different
proteases elicits distinct signaling responses in endothelial cells.
PAR1 and EPCR localize to lipid rafts and associate with
caveolin-1 (15), but whether caveolae are essential for APC
signaling and endothelial barrier protection has not been deter-
mined. To examine the role of caveolae in thrombin and APC
signaling, we generated endothelial cells stably expressing a
caveolin-1 shRNA to ablate caveolin-1 expression (Fig. 3A) (18).
Importantly, the amount of cell surface PAR1 and EPCR was
similar in control and caveolin-1–lacking cells (Fig. S5), suggest-
ing that caveolae deficiency does not globally disrupt protein
expression at the cell surface. Interestingly, thrombin activation
of ERK1/2 was comparable in control and caveolin-1–deficient
endothelial cells (Figs. 3B and S6), indicating that caveolae are
not essential for thrombin signaling. Remarkably, however,
activation of ERK1/2 by APC was lost in caveolin-1–deficient
endothelial cells examined at early and late times (Figs. 3C, S6,
and S7). These findings suggest that caveolae are critical for
activation of PAR1 signaling by APC but not thrombin.
We next investigated the function of caveolae in APC-induced
Rac1 activation and endothelial barrier protection. APC stim-
ulated a marked increase in Rac1 activation in control cells that
was virtually abolished in endothelial cells lacking caveolin-1
(Fig. 4A). These findings provide further evidence that caveolae
are essential for APC activation of PAR1 signaling. Moreover,
APC pretreatment failed to protect caveolin-1–deficient endo-
thelial cells from thrombin-induced endothelial barrier perme-
ability (Fig. 4B), consistent with loss of APC signaling in
caveolin-1–defective cells. Thus, the compartmentalization of
PAR1 in caveolae is essential for APC activation of PAR1
protective signaling in endothelial cells.
To determine how APC prevents thrombin from causing
endothelial barrier dysfunction, we examined whether APC
desensitizes cells to thrombin signaling. Thrombin caused
robust ERK1/2 activation in naïve cells (Fig. 5A). By contrast,
thrombin-stimulated ERK1/2 activation was markedly reduced
in cells pretreated with APC (Fig. 5A). Interestingly, inhibition
of thrombin-induced ERK1/2 activation by APC required
caveolin-1 expression (Fig. 5B), consistent with a critical role
for caveolae in APC signaling. Moreover, thrombin-induced
RhoA activation and p38 kinase activation were considerably
attenuated in cells pretreated with APC (Figs. 5C and S8),
providing further evidence that APC desensitizes cells to
thrombin signaling to promote endothelial barrier protection.
Signaling by PAR2 agonist peptide, and UTP, an agonist for
endogenous purinergic receptors, was unperturbed by APC
pretreatment, indicating that endothelial cells are generally
responsive to GPCR activation after APC pretreatment (data
not shown).
Agonist-induced PAR1 phosphorylation initiates receptor de-
sensitization (19, 20). Thus, we determined whether APC pro-
motes phosphorylation of endogenous PAR1 in endothelial cells.
Phosphorylated PAR1 was detected after thrombin incubation
and migrated as a broad band at 64 kDa (Fig. 6A) (21). Cells
exposed to APC also showed an increase in PAR1 phosphory-
lation, which was detected as multiple high–molecular-weight
species migrating at and above 64 kDa (Fig. 6A). Strikingly, in
APC-pretreated cells, thrombin and APC failed to induce
phosphorylation of PAR1 (Fig. 6A). These data suggest the APC
Fig. 1. PAR1 is essential for thrombin and APC signaling in endothelial cells.
(A and B) Serum-deprived control and PAR1 shRNA-expressing EA.hy926 en-
dothelial cells were incubated with thrombin or APC (0.5 U/ml hirudin) for 5
minutes at 37 °C. ERK1/2 activity was determined by immunoblotting and
quantitated as described in Fig. S3. Data are representative of three indepen-
dent experiments.
Fig. 2. Thrombin and APC differentially regulate endothelial barrier per-
meability and Rho activation. (A) Confluent EA.hy926 cells were preincubated
with or without 10 nM APC for 3 hours at 37 °C in medium containing 0.5 U/ml
hirudin, and then treated with 10 nM APC or 10 nM thrombin (Th) for 20
minutes at 37 °C. Endothelial barrier permeability was as described in SI
Methods (10). Data (mean  SD, n  3) are representative of three indepen-
dent experiments. (B and C) Cells were incubated with or without 10 nM
thrombin (Th) or 10 nM APC (0.5 U/ml hirudin) at 37 °C. Cells were lysed, and
activated RhoA and Rac1 were detected by immunoblotting. Data are repre-
sentative of three separate experiments. (D) Control and PAR1-deficient en-
dothelial cells were incubated with or without 10 nM APC for 5 minutes at
37 °C, and activation of Rac1 was determined. Data (mean  SE) are expressed
as the fold-increase over untreated control and are the averages of three
independent experiments. The difference between Rac1 activation induced
by APC in control versus PAR1-deficient cells was significant (* P  0.05).
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regulates thrombin signaling at the level of the receptor to
promote endothelial barrier protection.
In addition to phosphorylation, receptor internalization and
lysosomal degradation also regulate PAR1 signaling (22). We
therefore examined whether APC effects PAR1 trafficking.
Thrombin induced rapid and robust PAR1 internalization (Fig.
6C). In contrast, APC failed to promote PAR1 internalization
even at high concentrations (Fig. 6C), consistent with retention
of PAR1 on the cell surface (23). Remarkably, however, throm-
bin stimulated comparable increases in PAR1 internalization in
both untreated and APC treated cells (Fig. 6D), suggesting that
APC exposure does not prevent thrombin-induced PAR1
internalization.
We further investigated whether thrombin promotes PAR1
degradation in cells exposed to APC. Thrombin caused a shift in
mobility and a significant loss of PAR1 protein in control cells
(Fig. 6B), consistent with thrombin cleavage and degradation of
activated PAR1. Activation of PAR1 with the peptide agonist
TFLLRNPDNK also decreased receptor protein without alter-
ing receptor mobility, as expected (Fig. 6B). To our surprise,
prolonged exposure to APC failed to induce a significant change
in PAR1 mobility or amount of receptor protein detected
compared to control cells (Fig. 6B). Moreover, the extent of
PAR1 degradation induced by thrombin and peptide agonist was
comparable in APC-treated and untreated cells (Fig. 6B). To-
gether these studies suggest that APC desensitizes cells to
thrombin signaling by inducing PAR1 phosphorylation, but
causes limited receptor cleavage and negligible internalization
and degradation.
Discussion
In the present study, we define a novel function for caveolae in
protease-selective signaling by PAR1. We show that endogenous
PAR1 is required for thrombin and APC signaling in endothelial
cells. We further demonstrate that caveolin-1 is essential for
activation of PAR1 signaling by APC but not thrombin, indicat-
ing that caveolae are critical for protease-selective signaling by
PAR1. Caveolae are also required for activation of PAR2 by
tissue factor-factor VIIa but not the synthetic peptide agonist in
transformed cells (24), consistent with a role for caveolae in
protease-selective signaling. Moreover, a function for lipid rafts
but not caveolae, in thrombin-induced cytoskeletal changes in
endothelial cells has previously been reported (25). The cyto-
protective and endothelial barrier protective effects of APC are
also disrupted by methyl--cyclodextrin, a cholesterol-chelating
agent, indicating a role for lipid rafts (16). However, the function
of caveolae, a subtype of lipid rafts, in the regulation of APC
signaling has not been previously examined. Our studies suggest
that APC promotes protective effects by desensitizing endothe-
lial cells to thrombin signaling. We found that APC stimulates
PAR1 phosphorylation and inhibits thrombin signaling but
causes limited receptor cleavage, and negligible internalization
and degradation. Together these findings suggest that APC-
mediated endothelial protective signaling requires compartmen-
talization of PAR1 in caveolae and a novel mechanism of PAR1
desensitization to control receptor signaling.
The molecular mechanism by which APC distinctly activates
PAR1 signaling remains unclear. PAR1 is essential for APC
signaling, but whether APC induces an active PAR1 conforma-
tion similar to thrombin is not known. Previous studies have
shown that APC has the capacity to cleave PAR1, albeit with
considerably less efficiency than thrombin (9, 26). However,
whether APC cleavage of PAR1 is the only critical determinant
that facilitates PAR1 activation of barrier protective signaling is
not known. Thrombin cleaves the majority of PAR1, causing a
shift in receptor mobility and induces receptor degradation,
whereas the peptide agonist TFLLRNPNDK promotes PAR1
degradation but not cleavage and hence does not alter receptor
mobility (Fig. 6). We show here that APC induces PAR1
signaling and phosphorylation but causes a minimal change in
receptor mobility. However, signaling by catalytically inactive
APC is markedly inhibited compared to fully active APC (Fig.
S9), suggesting that activation of PAR1 by APC requires pro-
teolytic activity. Interestingly, we also show that prolonged APC
incubation does not prevent thrombin-induced PAR1 cleavage,
internalization, or degradation. Thus, in endothelial cells ex-
posed to APC, the majority of PAR1 is retained on the cell
surface and susceptible to thrombin cleavage. Our findings raise
the intriguing possibility that APC activates a subpopulation of
PAR1 compartmentalized in caveolae and stabilizes an active
receptor conformation that may be distinct from noncaveolar
localized activated PAR1.
Fig. 3. Caveolin-1 is critical for APC but not thrombin, activation of PAR1 signaling. (A) Control and caveolin-1 (CAV1) shRNA expressing EA.hy926 cell lysates
were immunoblotted with an anti–caveolin-1 antibody. (B and C) Control and caveolin-1 (CAV1)–deficient cells were incubated with thrombin or APC for 5
minutes at 37 °C, and activation of ERK1/2 was examined by immunoblotting and quantitated as shown in Fig. S6. Data are representative of three independent
experiments.
Fig. 4. Caveolin-1 is essential for APC-induced Rac1 activation and endothe-
lial barrier protection. (A) Control and caveolin-1 (CAV1) deficient cells were
incubated with or without 10 nM APC at 37 °C, and Rac1 activation was
determined. Data (mean  SE) are expressed as fold-increase over control and
are the averages of three different experiments. The difference between Rac1
activation induced by APC in control versus CAV-1 deficient cells was signifi-
cant (* P  0.05). (B) Control and CAV-1–deficient cells were treated with or
without 10 nM APC for 3 hours at 37 °C and then incubated with 10 nM
thrombin (Th) or 10 nM APC for 10 minutes at 37 °C, and permeability was
monitored. Data (mean  SE) are the averages of three independent exper-
iments performed in triplicate. The difference between thrombin-induced
permeability in control versus CAV-1– deficient cells was significant
(* P  0.05).









How can activation of the same receptor by two different
proteases elicit distinct cellular responses? If APC activates
PAR1 through cleavage and unmasking of the tethered ligand
like thrombin a similar active receptor conformation would be
induced. However, the extent of PAR1 activation by APC would
be different from thrombin, which efficiently cleaves the recep-
tor (26). In this case, we would expect to observe quantitative,
not qualitative, differences in signaling. Thrombin-activated
PAR1 couples to Gq, G12/13, and RhoA signaling, which
induces endothelial barrier dysfunction (2). In contrast, we show
that APC-activated PAR1 stimulates Rac1, but not RhoA,
signaling and promotes endothelial barrier protection. Thus, the
activation of PAR1 by APC may result in a distinct active
receptor conformation that selectively couples to different sig-
naling pathways. We further show that caveolin-1 is essential for
APC but not thrombin activation of PAR1 signaling and endo-
thelial barrier protective effects, suggesting that PAR1 localiza-
tion to caveolae is critical for protease-selective signaling. Pre-
vious studies have shown that the APC co-factor EPCR, PAR1,
Gq and Gi partition into lipid rafts and interact with caveolin-1
(15, 16, 27). The barrier protective signaling induced by APC is
also blocked by pertussis toxin, suggesting a role for Gi/o
proteins in this process (15). Moreover, the binding of APC to
EPCR facilitates efficient PAR1 cleavage in lipid rafts and
endothelial barrier signaling, suggesting that caveolae localiza-
tion may induce a distinct active receptor conformation that
elicits barrier protective signaling (28). Thus, PAR1, EPCR, and
Gi/o proteins localize to caveolae and may exist as a preas-
sembled complex poised to signal after PC binding to EPCR and
generation of APC. In contrast, caveolin-1 is not essential for
thrombin activation of PAR1 signaling (Figs. 3 and 4), indicating
that caveolin-1 modulates PAR1 signaling only when selectively
activated by APC and not by thrombin in endothelial cells.
Our studies provide new insight into the molecular mecha-
nisms responsible for protease-selective signaling by PAR1.
Fig. 5. APC desensitizes PAR1 to thrombin signaling. (A) EA.hy926 cells were
preincubated with or without 10 nM APC for 1 hour at 37 °C and then
stimulated with thrombin (Th) or APC at 37 °C; ERK1/2 activation was exam-
ined by immunoblotting. Data (mean  SE) are expressed as the fold-increase
over untreated control and are the averages of three separate experiments.
The difference between thrombin-induced ERK1/2 activation in untreated
versus APC-pretreated cells was significant (* P  0.05). (B) Control and
caveolin-1 (CAV1)–deficient cells were preincubated with 10 nM APC for 1
hour at 37 °C and then stimulated with or without 10 nM thrombin (Th) at
37 °C, and ERK1/2 activation was determined. (C) Cells were pretreated with
or without 10 nM APC for 1 hour at 37 °C and then stimulated with or without
10 nM thrombin (Th) at 37 °C, and activated RhoA was examined. Similar
findings were observed in two independent experiments.
Fig. 6. APC stimulates PAR1 phosphorylation but not internalization or degradation. (A) EA.hy926 cells labeled with [32P]orthophosphate were preincubated with
or without 10 nM APC for 3 hours at 37 °C and then stimulated with 10 nM Th or 10 nM APC for 3 minutes at 37 °C. Immunoprecipitated 32P-labeled PAR1 was detected
as described (21). Similar results were observed in three independent experiments. (B) Cells pretreated with or without 10 nM APC for 3 hours at 37 °C, and then
incubated with 10 nM thrombin (Th), 10 nM APC, or 100 M TFLLRNPNDK for 90 minutes at 37 °C and the amount of PAR1 was determined as described (21). Asterisk
indicates detection of the heavy and light chains of the immunoprecipitating antibodies. Data (mean  SE) are expressed as the fraction of PAR1 protein remaining
compared with untreated control and are the averages of three independent experiments. A significant difference (* P  0.05 or ** P  0.01) was detected between
agonist-treated versus untreated controls in some cases. (C) Cells were incubated in the absence or presence of thrombin (Th) or APC for various times at 37 °C and the
amount of PAR1 remaining on the cell surface was quantitated by enzyme-linked immunosorbent assay (ELISA). Data (mean  SD, n  3) are representative of three
independent experiments. The difference between thrombin and untreated control at various times was significant (* P  0.05). (D) Cells were preincubated with or
without 10 nM APC for 3 hours at 37 °C, washed, and then treated with or without 10 nM thrombin (Th) for various times at 37 °C. Cells were fixed and processed, and
the amount of PAR1 remaining on the cell surface was measured by ELISA. Data (mean  SD, n  3) are from one representative experiment.
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Evidence presented here suggests that compartmentalization of
PAR1 in caveolae facilitates selective endothelial barrier–
protective signaling. The molecular determinants that specify the
targeting of PAR1 to caveolae are not known but may involve
unique posttranslational modifications. The novel regulation of
PAR1 signaling by APC is also critical for endothelial barrier
protection. We previously showed that PAR1 trafficking is
essential for the fidelity of thrombin signaling (22, 29). However,
in contrast to thrombin, our findings here suggest that APC
imparts a novel mechanism for regulation of PAR1 signaling that
involves receptor phosphorylation but not internalization or
degradation. Thus, in future pursuits it will be important to
determine the mechanism(s) by which endothelial cells desen-
sitize and resensitize to APC signaling.
Materials and Methods
Reagents. See SI Methods.
Cells. Human umbillical vein endothelial cell (HUVEC)–derived EA.hy926 cells
were provided by C. Edgell (University of North Carolina, Chapel Hill, NC) and
maintained as described (30). EA.hy926 cells expressing PAR1 and caveolin-1
shRNA were generated as described in SI Methods.
Permeability Assay. See SI Methods.
RhoA and Rac1 Activity Assays. See SI Methods.
Kinase Assays. EA.hy926 cells plated at 0.7  105 cells per well in 24-well dishes
and grown for 2 days were serum-starved overnight. After incubations, cell
lysates were prepared, and ERK1/2 and p38 activity were determined as
described elsewhere (17).
Phosphoinositide Hydrolysis. EA.hy926 cells were plated at 6  104 cells per well
in 24-well dishes and labeled overnight with 1 Ci/ml of myo-[3H]inositol
(American Radiolabeled Chemicals, St. Louis, MO), treated with agonists;
accumulated [3H]inositol phosphates (IPs) were measured as previously de-
scribed (31).
Cell Surface Enzyme-Linked Immunosorbent Assay. EA.hy926 cells were plated
at 0.7  105 cells per well in 24-well culture dishes. After incubations, cells were
fixed and processed as previously described (31). Cell surface PAR1 was de-
tected using a rabbit polyclonal anti-PAR1 antibody (29, 32), and EPCR was
detected using a monoclonal anti-EPCR JRK 1500 antibody provided by C.
Esmon (Oklahoma Medical Research Foundation, Oklahoma City, OK).
PAR1 Phosphorylation and Degradation. EA.hy926 cells plated at 5  105 cells
per well in six-well dishes were grown overnight, and PAR1 degradation was
determined as described elsewhere (21) and in SI Methods.
Data Analysis. Data were analyzed using Prism 4.0 software (GraphPad), and
statistical significance was determined using InStat 3.0 (GraphPad). Group
comparisons were made using an unpaired t test.
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